Pfizer (NYSE: PFE) revises 2025 revenue guidance and outlines 2026 outlook

Rhea-AI Filing Summary

Pfizer Inc. furnished a regulatory disclosure stating that it issued a press release providing its full-year 2026 financial guidance and revising its full-year 2025 revenue guidance.

The company reaffirmed all other components of its full-year 2025 financial guidance in the same press release, which is attached as an exhibit to the disclosure.

Insights

Pharmaceutical equity analyst

Pfizer updates guidance for 2025 revenue and introduces 2026 outlook, with overall 2025 framework reaffirmed.

Pfizer released new forward-looking information by providing full-year 2026 guidance and adjusting its revenue guidance for 2025. This type of disclosure helps frame market expectations for future performance and is furnished under Regulation FD to ensure broad, simultaneous access to the same information.

The company explicitly reaffirmed all other components of its full-year 2025 financial guidance, indicating that only the revenue element has been revised while the rest of the framework remains unchanged. The detailed figures and assumptions are contained in the press release identified as Exhibit 99.1.

Attention will likely center on the magnitude and direction of the 2025 revenue revision and the initial 2026 guidance ranges set out in the December 16, 2025 press release, since those details shape expectations reflected in future company filings.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

0000078003false00000780032025-12-162025-12-160000078003us-gaap:CommonStockMember2025-12-162025-12-160000078003pfe:NotesDue20271.000Member2025-12-162025-12-160000078003pfe:NoteDue20292.875Member2025-12-162025-12-160000078003pfe:NoteDue20323.250Member2025-12-162025-12-160000078003pfe:NoteDue20373.875Member2025-12-162025-12-160000078003pfe:NoteDue20454.250Member2025-12-162025-12-16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 16, 2025

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware			1-3619			13-5315170
(State or other			(Commission File			(I.R.S. Employer
jurisdiction of			Number)			Identification No.)
incorporation)

66 Hudson Boulevard East						10001-2192
New York,			New York			(Zip Code)

(Address of principal executive offices)

Registrant’s telephone number, including area code:

(212) 733-2323

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.05 par value

PFE

New York Stock Exchange

1.000% Notes due 2027

PFE/27

New York Stock Exchange

2.875% Notes due 2029

PFE/29

New York Stock Exchange

3.250% Notes due 2032

PFE/32

New York Stock Exchange

3.875% Notes due 2037

PFE/37A

New York Stock Exchange

4.250% Notes due 2045

PFE/45

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐

Item 7.01.     Regulation FD Disclosure.

On December 16, 2025, Pfizer Inc. issued a press release that provided its full-year 2026 guidance and revised its full-year 2025 Revenue guidance while reaffirming all other components of its full-year 2025 financial guidance. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The information furnished pursuant to this “Item 7.01 – Regulation FD Disclosure”, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or the Securities Act, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Exhibit Description

Exhibit 99.1

Press Release of Pfizer Inc. dated December 16, 2025

104

Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			PFIZER INC.
			By:			/s/ Margaret M. Madden
						Margaret M. Madden
						Senior Vice President and Corporate Secretary
						Chief Governance Counsel

Dated: December 16, 2025

FAQ

What did Pfizer Inc. (PFE) disclose in this SEC report?

Pfizer Inc. disclosed that it issued a press release providing its full-year 2026 financial guidance and updating its full-year 2025 revenue guidance.

Did Pfizer (PFE) change its full-year 2025 guidance?

Pfizer revised its full-year 2025 revenue guidance but reaffirmed all other components of its full-year 2025 financial guidance.

What information about 2026 did Pfizer (PFE) provide?

Pfizer provided full-year 2026 financial guidance in the press release referenced in the report.

Where can investors find Pfizers updated guidance details?

The detailed guidance figures are contained in Pfizers press release, which is furnished as Exhibit 99.1 to the report and incorporated by reference.

Under which item was this Pfizer (PFE) disclosure made?

The disclosure was made under Item 7.01, Regulation FD Disclosure.

Is Pfizers guidance press release considered filed for liability purposes?

No. The information furnished under Item 7.01, including Exhibit 99.1, is not deemed filed for purposes of Section 18 of the Exchange Act.